Avalo Therapeutics Inc
(AVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | |
| Cash Flows From Operating Activities | |
| Net Income | -13,040 |
| Depreciation Amortization | 20 |
| Other Working Capital | 760 |
| Other Operating Activity | 780 |
| Operating Cash Flow | $-11,480 |
| Cash Flows From Investing Activities | |
| PPE Investments | -20 |
| Investing Cash Flow | $-20 |
| Cash Flows From Financing Activities | |
| Other Financing Activity | 5,410 |
| Financing Cash Flow | $5,410 |
| Beginning Cash Position | 9,510 |
| End Cash Position | 3,420 |
| Net Cash Flow | $-6,090 |
| Free Cash Flow | |
| Operating Cash Flow | -11,480 |
| Free Cash Flow | -11,480 |